Patent portfolio

Patent portfolio

CANCER

Novel inhibitors of Aurora A kinase
Ref. CRG-0123

A novel series of compounds which specifically inhibit the effects of Aurora A kinase. Tested in vitro and in human cell culture.

Download Technical sheet here

Adenovirus for tumor treatment
Ref. CRG-0113

A new conditionally replicating adenovirus containing a promoter that shows high selectivity and antitumoral efficacy in pancreatic tumors and metastases in vivo.

Download Technical sheet here

Novel protein complex as a target for cancer treatment
Ref. CRG-0100

New protein-protein interaction implied in key cellular processes related to tumor development.

Download Technical sheet here

Mutant TRAIL protein with enhanced cancer treatment properties
Ref. CRG-0032

In silico design and development of a TRAIL protein variant with an increased binding affinity towards the DR4 receptor.

Download Technical sheet here

Mutant TRAIL protein with enhanced cancer treatment properties
Ref. CRG-0052

In silico design and development of a TRAIL protein variant with an increased binding affinity towards the DR5 receptor.

Download Technical sheet here

Use of CPEB4 for prognosis or diagnosis of pancreatic cancer
Ref. CRG-0322

Novel target with potential interest in pancreatic ductal adenocarcinoma.

Download Technical sheet here

DERMATOLOGY

Kit and procedure to determine predisposition of developing psoriasis.
Ref. CRG-0138

Method and kit for microarray comparative genomic hybridization analysis system. The results can predict the predisposition of an individual to develop psoriasis.

Download Technical sheet here

HIV/AIDS

Screening method for compounds to reactivate HIV latency stage.
Ref. CRG-0026

Screening method to detect compounds that can inhibit the latency stage of HIV, making antiretroviral therapy more effective.

Download Technical sheet here

NEURODEGENERATIVE DISEASES

Transcription repression of CAG repeats in Huntington’s disease.
Ref. CRG-0307

Novel zinc finger proteins (ZFP) that selectively bind and repress the expression of the mutant huntingtin gene. Tested in an R6/2 mouse model of Huntington’s Disease.

Download Technical sheet here

Compounds for the treatment of neurodegenerative diseases.
Ref. CRG-0382

A novel target and family of compounds with potential interest in neurodegenerative diseases treatment.

Download Technical sheet here

OSTEOPOROSIS

Novel RANKL Antagonists for the treatment of osteoporosis and cancer.
Ref. CRG-0352

Novel strategy for blocking the RANKL/RANK pathway to prevent bone loss and/or tumor infiltration, with potential for the treatment of osteoporosis, diabetes and cancer. The strategy of design of synthetic ligands can be applied to other members of the TNF superfamily for the treatment of inflammatory and autoimmune diseases.

Download Technical sheet here

TOOLS AND REAGENTS

P53 zinc finger nucleases optimised by yeast 1-hybrid.
Ref. CRG-0414/A

A novel functional zinc finger nucleases (ZFN) against two DNA sites in the human p53.

Download Technical sheet here